In 2022, the most recent edition (5th-WHO5) was released, which still included CMML but introduced changes: JMML was removed, aCML was renamed to MDS/MPN with neutrophilia (mainly to avoid confusion with CML), MDS/MPN-RS-T was renamed as MDS/MPN with thrombocytosis and SF3B1 mutation (MDS/MPN-T-SF3B1), and MDS/MPN-unclassifiable was termed as MDS/MPN not otherwise specified (MDS/MPN-NOS) [2]. Here, SF3B1 is linked to myeloproliferative neoplasm.